Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EZN-2208 in Pediatric and Young Adult Solid Tumors
NCT01295697Phase 2Terminated
- Sponsor
- Enzon Pharmaceuticals
- Start
- Feb 2010
- Primary completion
- Aug 2012
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of etirinotecan pegol in solid tumor, sponsored by Enzon Pharmaceuticals. Started Feb 2010; status: terminated.
02
Drugs
etirinotecan pegol
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT01295697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01295697.